Key Insights on Gross Profit: Veracyte, Inc. vs Ligand Pharmaceuticals Incorporated

Biotech Giants: Veracyte's Rise vs Ligand's Fluctuations

__timestampLigand Pharmaceuticals IncorporatedVeracyte, Inc.
Wednesday, January 1, 20145540200021584000
Thursday, January 1, 20156610700028006000
Friday, January 1, 201610340200039623000
Sunday, January 1, 201713573600043758000
Monday, January 1, 201824511600058930000
Tuesday, January 1, 201910893500083845000
Wednesday, January 1, 202015600000076028000
Friday, January 1, 2021214957000145114000
Saturday, January 1, 2022143418000194954000
Sunday, January 1, 202396265000248148000
Loading chart...

Igniting the spark of knowledge

A Tale of Two Biotechs: Veracyte, Inc. vs Ligand Pharmaceuticals

In the dynamic world of biotechnology, financial performance can be as volatile as the science itself. Over the past decade, Veracyte, Inc. and Ligand Pharmaceuticals Incorporated have showcased intriguing trajectories in their gross profit margins. From 2014 to 2023, Ligand Pharmaceuticals saw a peak in 2018, with gross profits soaring by approximately 340% from their 2014 figures. However, the subsequent years witnessed a decline, with 2023 profits dropping by nearly 60% from their 2018 high.

Conversely, Veracyte, Inc. has demonstrated a consistent upward trend, culminating in a remarkable 1,050% increase in gross profit from 2014 to 2023. This growth trajectory highlights Veracyte's strategic advancements and market positioning. As the biotech landscape continues to evolve, these companies exemplify the diverse paths to financial success.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025